
Central Pharmaceutical JSC No. 3 Adjusts Valuation Amid Mixed Financial Indicators and Market Sentiment
2025-10-07 20:37:09Central Pharmaceutical JSC No. 3 has experienced a recent evaluation adjustment, reflecting significant changes in its financial metrics. The company now holds a fair valuation grade, supported by a competitive P/E ratio, strong returns on capital and equity, and a favorable enterprise value to EBITDA ratio, despite a bearish technical trend.
Read MoreNo announcement available
Corporate Actions
No corporate action available






